Poziotinib in Patients With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation
Status:
Terminated
Trial end date:
2020-04-13
Target enrollment:
Participant gender:
Summary
This is a Phase 2, open-label, multicenter study to evaluate the efficacy and the
safety/tolerability of poziotinib in two patient cohorts for up to 114 previously treated
NSCLC patients with any systemic therapy (57 patients with EGFR exon 20 insertion mutations
and 57 patients with HER2 exon 20 insertion mutations).